ARS Pharmaceuticals Hits New 52-Week Low at $8.45 Amid Financial Struggles

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 8.45 as of October 31, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop by 39.13% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's recent financial results have raised concerns, particularly following a negative report in March 2025 after three consecutive quarters of positive performance. Key metrics indicate challenges, including a return on equity of -24.97% and a debt-to-equity ratio of -1.25. Additionally, the operating profit for the latest quarter was reported at USD -47.33 million, reflecting ongoing financial strain.

With a market capitalization of USD 1,057 million, ARS Pharmaceuticals is navigating a difficult landscape, characterized by rising raw material costs, which increased by 29.47% year-over-year. The stock's price-to-book ratio stands at 5.50, further highlighting the challenges the company faces in maintaining investor confidence amidst these financial hurdles.